DARZALEX® SC practical guidance

It seems your browser is blocking 3rd party cookies which are required to display videos. To resolve this issue, please update your cookie settings to allow these 3rd party cookies.

DARZALEX® SC dosing and treatment schedules

  • Single-use vial, fixed dose of 1800 mg DARZALEX® and 30000 units of recombinant human hyaluronidase PH20 (ENHANZE® drug delivery technology)[1][2]

    • Fixed dose reduces wastage, risk of miscalculating dose and preparation time
  • Administration from the first dose of DARZALEX® SC treatment, and from the next scheduled dose in patients who are currently on DARZALEX® IV[1]
  • Vials do not require filtration or IV pump[1]
  • DARZALEX® solution for injection is a colourless-to-yellow liquid[1]
  • Treatment schedules with DARZALEX® SC remain the same, and DARZALEX® SC is available in all approved DARZALEX® IV indications[1]

Quick downloads

SC Checklist beginning of treatment

Includes a first use checklist of Darzalex® SC.

Darzalex® SC Practical Guide

Includes DARZALEX® SC handling and administration info, pre and post-injection medications, and more

AE: adverse event

IV: intravenous

MOA: mode of action

rHuPH20: recombinant human hyaluronidase

PH20 SC: subcutaneous

Titular da Autorização de Introdução no Mercado: Janssen-Cilag International NV, Turnhoutseweg 30, B-2340 Beerse, Bélgica.
Para mais informações deverá contactar o Representante do Titular da Autorização de Introdução no Mercado: Janssen-Cilag Farmacêutica, Lda.

Medicamento de receita médica restrita, de utilização reservada a certos meios especializados.

Antes de prescrever consulte o RCM completo.

RCM de Darzalex®, veja aqui

CP-287862 - March 2022